Acarbose in Combination With Standard Therapy in Metastatic Renal Cell Carcinoma (RCC)

Summary

The purpose of this study is to determine the safety and tolerability of acarbose in combination of immunotherapy based standard of care therapy in advanced renal cell carcinoma patients.

Timeline

Start

2025-12-31

Primary completion

2026-10

Completion

2026-12

Outcome

Outcome not reported

Stopped: “due to overall cost of the study”

Drugs

Indications